1046767-57-0

Basic information

• Product Name: 1-(9H-fluoren-9-yl)methyl 2-benzyl (2S,3aS,6aS)-hexahydro-cyclopenta[b]pyrrole-1,2(2H)-dicarboxylate
• Synonyms: 1-(9H-fluoren-9-yl)methyl 2-benzyl (2S,3aS,6aS)-hexahydro-cyclopenta[b]pyrrole-1,2(2H)-dicarboxylate
• CAS NO: 1046767-57-0
• Molecular Weight: 467.565
• Mol File: 1046767-57-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(9H-fluoren-9-yl)methyl 2-benzyl (2S,3aS,6aS)-hexahydro-cyclopenta[b]pyrrole-1,2(2H)-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(9H-fluoren-9-yl)methyl 2-benzyl (2S,3aS,6aS)-hexahydro-cyclopenta[b]pyrrole-1,2(2H)-dicarboxylate(1046767-57-0)
• EPA Substance Registry System: 1-(9H-fluoren-9-yl)methyl 2-benzyl (2S,3aS,6aS)-hexahydro-cyclopenta[b]pyrrole-1,2(2H)-dicarboxylate(1046767-57-0)

Safety Data

• Hazardous Substances Data: 1046767-57-0(Hazardous Substances Data)

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 93779-31-8 benzyl (1S,3S,5S)-2-azabicyclo<3.3.0>octane-3-carboxylate 

Downstream Products

• 130309-34-1 (2S,3aS,6aS)-1-{[(9H-Fluoren-9-yl)methoxy]carbonyl}octahydrocyclopenta[b]pyrrole-2-carboxylic acid 

Relevant articles and documents

NITRIC OXIDE DONOR COMPOUNDS

The invention relates to nitric oxide donor compounds and their use for treatingcardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metabolismdysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compoundsof the invention and composition comprising at least one nitric oxide releasing compoundsaccording to the inventionand at least one 15 therapeutic agent.